newsfilter
← Latest News
GlobeNewswire·

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results

Updated interim data from the Phase 1/2a bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window and potential to achieve a best-in-class profile in NETsMeaningful antitumor